Drug Details

General Information of the Drug (ID: DR3220)
Name
Volasertib
Synonyms
Volasertib; 755038-65-4; BI 6727; Volasertib (BI 6727); BI6727 (Volasertib); BI-6727; UNII-6EM57086EA; BI6727; 6EM57086EA; N-((1s,4S)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)amino)-3-methoxybenzamide; N-(Trans-4-(4-(cyclopropylMethyl)piperazin-1-yl)cyclohexyl)-4-(((R)-7-ethyl-8-isopropyl-5-Methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-yl)aMino)-3-MethoxybenzaMide; N-[4-[4-(cyclopropylmethyl)piperazin-1-yl]cyclohexyl]-4-[[(7R)-7-ethyl-5-methyl-6-oxo-8-propan-2-yl-7H-pteridin-2-yl]amino]-3-methoxybenzamide; N-{trans-4-[4-(Cyclopropylmethyl)piperazin-1-Yl]cyclohexyl}-4-{[(7r)-7-Ethyl-5-Methyl-8-(1-Methylethyl)-6-Oxo-5,6,7,8-Tetrahydropteridin-2-Yl]amino}-3-Methoxybenzamide; Volasertib [USAN:INN]; IBI; Volasertib (USAN); BI6727,Volasertib; Volasertib(BI6727); BI6727 - Volasertib; Volasertib (BI6727); BI 6727 (Volasertib); BI6727 (Volasertib)/; cc-629; MLS006011195; SCHEMBL738946; GTPL7947; SCHEMBL2169101; SCHEMBL9888052; CHEMBL1233528; CHEMBL4284151; SCHEMBL21916558; BCPP000341; C34H50N8O3; AOB87138; BCP02405; EX-A1364; ABP000330; BDBM50402023; MFCD20926414; NSC757149; NSC800965; s2235; ZINC39716290; AKOS030257530; ZINC100071772; ZINC248087828; BCP9000403; CCG-264952; CS-0274; DB12062; NSC-757149; NSC-800965; PB19742; NCGC00263087-01; NCGC00263087-02; NCGC00263087-03; NCGC00263087-12; NCGC00263087-15; NCGC00485964-01; AC-32844; AS-16996; HY-12137; SMR004702964; SW218140-2; X7437; D10182; Q-4502; SR-03000003275; Q7939986; SR-03000003275-1; Benzamide, N-(trans-4-(4-(cyclopropylmethyl)-1-piperazinyl)cyclohexyl)-4-(((7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl)amino)-3-methoxy-; N-((trans)-4-(4-(cyclopropylmethyl)piperazin-1-yl)cyclohexyl)-4-((R)-7-ethyl-8-isopropyl-5-methyl-6-oxo-5,6,7,8-tetrahydropteridin-2-ylamino)-3-methoxybenzamide; n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide; n-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7r)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxybenzamide
    Click to Show/Hide
Molecular Type
Small molecule
Disease Acute myeloid leukemia [ICD-11: 2A60] Phase 3 [1]
Structure
Click to Download Mol
2D MOL

3D MOL

    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C34H50N8O3
PubChem CID
10461508
Canonical SMILES
CCC1C(=O)N(C2=CN=C(N=C2N1C(C)C)NC3=C(C=C(C=C3)C(=O)NC4CCC(CC4)N5CCN(CC5)CC6CC6)OC)C
InChI
1S/C34H50N8O3/c1-6-28-33(44)39(4)29-20-35-34(38-31(29)42(28)22(2)3)37-27-14-9-24(19-30(27)45-5)32(43)36-25-10-12-26(13-11-25)41-17-15-40(16-18-41)21-23-7-8-23/h9,14,19-20,22-23,25-26,28H,6-8,10-13,15-18,21H2,1-5H3,(H,36,43)(H,35,37,38)/t25?,26?,28-/m1/s1
InChIKey
SXNJFOWDRLKDSF-XKHVUIRMSA-N
CAS Number
CAS 755038-65-4
TTD Drug ID
D00BYM
DrugBank ID
DB12062
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Vincristine      Catharanthus roseus     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model A-204 CVCL_1058 Embryonal rhabdomyosarcoma Homo sapiens
RD CVCL_1649 Embryonal rhabdomyosarcoma Homo sapiens
Rh18 CVCL_1659 Alveolar rhabdomyosarcoma Homo sapiens
Rh30 CVCL_0041 Alveolar rhabdomyosarcoma Homo sapiens
Rh41 CVCL_2176 Alveolar rhabdomyosarcoma Homo sapiens
RMS-1 CVCL_UF94 Embryonal rhabdomyosarcoma Homo sapiens
RMS-YM CVCL_A792 Embryonal rhabdomyosarcoma Homo sapiens
                    Experimental
                    Result(s)		 Volasertib exhibits antitumor activity and synergy with vincristine in alveolar rhabdomyosarcoma.
Target and Pathway
Target(s) Polo-like kinase 1 (PLK1)  Molecule Info  [3]
KEGG Pathway FoxO signaling pathway Click to Show/Hide
2 Cell cycle
3 Oocyte meiosis
4 Progesterone-mediated oocyte maturation
Pathway Interaction Database p73 transcription factor network Click to Show/Hide
2 ATR signaling pathway
3 PLK1 signaling events
4 FoxO family signaling
5 FOXM1 transcription factor network
6 Validated transcriptional targets of TAp63 isoforms
7 Polo-like kinase signaling events in the cell cycle
Reactome Polo-like kinase mediated events Click to Show/Hide
2 Golgi Cisternae Pericentriolar Stack Reorganization
3 APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
4 Phosphorylation of the APC/C
5 Phosphorylation of Emi1
6 Condensation of Prophase Chromosomes
7 Separation of Sister Chromatids
8 Resolution of Sister Chromatid Cohesion
9 Regulation of PLK1 Activity at G2/M Transition
10 Activation of NIMA Kinases NEK9, NEK6, NEK7
11 Loss of Nlp from mitotic centrosomes
12 Recruitment of mitotic centrosome proteins and complexes
13 Loss of proteins required for interphase microtubule organization?from the centrosome
14 Anchoring of the basal body to the plasma membrane
15 RHO GTPases Activate Formins
16 Mitotic Prometaphase
17 Cyclin A/B1 associated events during G2/M transition
WikiPathways Mitotic Telophase/Cytokinesis Click to Show/Hide
2 Mitotic Metaphase and Anaphase
3 Mitotic Prophase
4 Mitotic Prometaphase
5 Integrated Pancreatic Cancer Pathway
6 TNF alpha Signaling Pathway
7 Prostate Cancer
8 miR-targeted genes in muscle cell - TarBase
9 miR-targeted genes in lymphocytes - TarBase
10 miR-targeted genes in epithelium - TarBase
11 Integrated Breast Cancer Pathway
12 Integrated Cancer pathway
13 Mitotic G2-G2/M phases
14 Cell Cycle
15 APC/C-mediated degradation of cell cycle proteins
16 Regulation of toll-like receptor signaling pathway
References
Reference 1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Reference 2 Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies. Anticancer Res. 2016 Feb;36(2):599-609.
Reference 3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2168).
 Download Picture         KEGG Link